BioSpace News Archive

KalGene Pharmaceuticals Inc. announced that Anthony J. Giovinazzo, MBA, C. Dir. & A.C.C. has joined the Board of Directors of the company as an Executive Chairman.

Bicycle Therapeutics plc, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide technology, reported financial results for the second quarter ended June 30, 2021 and provided recent corporate updates.

AVROBIO Reports Second Quarter 2021 Financial Results and Provides Business Update

Imara Inc. today announced that the company has completed patient enrollment in the Ardent Phase 2b clinical trial of IMR-687, a potent small molecule inhibitor of PDE9, for the treatment of sickle cell disease (SCD).

Surface Oncology today reported financial results and corporate highlights for the second quarter 2021, and provided an update on anticipated corporate milestones.

Syros Pharmaceuticals today announced that it has entered into a clinical supply agreement with Roche.

Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels. Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarter

Intellia Therapeutics, Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, reported financial results for the second quarter ended June 30, 2021, and recent operational highlights.

Salarius Pharmaceuticals, Inc. today reported important corporate events and its financial results for the second quarter ended June 30, 2021.

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, reports its second quarter 2021 financial results and provides a corporate update.